Stanford Medicine study finds 6.5% risk of secondary blood cancers in 3 years after CAR-T therapy, with one fatal case due to immunosuppression.
Stanford Medicine study in the New England Journal of Medicine reports low risk of secondary blood cancers in patients receiving Chimeric Antigen Receptor T-cell (CAR-T) therapy to treat blood cancer. Despite the FDA's warning of a potential risk, the study indicates a risk of 6.5% in the three years after therapy, with the only fatal case attributed to immunosuppression caused by CAR-T cell therapy.
June 12, 2024
7 Articles